Recent Updates
Recently added Catalysts
RCUS Positive Sentiment

Arcus Biosciences Announces Commencement of Public Offering of Common Stock

Wednesday, October 21, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Arcus Biosciences has initiated an underwritten public offering of its common stock. The offering includes all shares being sold by the company. Additionally, there is a 30-day option for underwriters to purchase more shares. This move aims to support the company's ongoing development in cancer and immune disease treatments.

Market Sentiment Analysis

POSITIVE FACTORS

  • Arcus Biosciences is advancing its public offering.
  • The company focuses on cancer and immune disease therapies.
  • The offering could enhance funding for future developments.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+65%
120-day peak, hindsight
Typical move
2.8%
average across 10 past catalysts
Cash runway
~17 mo
Low dilution risk
Lead asset
Etrumadenant
Phase 1 · Prostatic Neoplasms, Castration-Resistant

Full Press Release Details

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE: RCUS), a late clinical-stage biopharmaceutical company focused on developing differentiated molecules and combination therapies for the treatment of cancer and immune diseases, today announced that it has commenced an underwritten public offering of its common stock. All of the shares of common stock are being offered by Arcus Biosciences. In addition, Arcus Biosciences intends to grant the underwriters a 30-day option to purchase

Frequently Asked Questions

What is the purpose of the public offering?

The offering aims to support funding for Arcus Biosciences' development efforts.

Who is offering the common stock?

All shares are being offered by Arcus Biosciences itself.

Is there an option for underwriters?

Yes, underwriters have a 30-day option to purchase additional shares.

What is Arcus Biosciences focused on?

The company focuses on developing therapies for cancer and immune diseases.

ShareAdd on Google
Tags: RCUS Arcus Biosciences common stock cancer therapies biopharmaceutical
Last updated: Oct 21, 2026

Biotech snapshot

Cash runway
$775M liquidity · $40M/mo burn
~17 mo
Low dilution risk
Lead asset
EtrumadenantPhase 1
Prostatic Neoplasms, Castration-Resistant →

Catalyst track record

+65%
best trade around RCUS's most recent catalyst

Peak hindsight return over a 120-day window, across 10 tracked FDA/PDUFA catalysts for RCUS.

See every catalyst's timing & PoA →